Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

ACON 11.15.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-21
Name of Upcoming Event:Virtual Investor Summit Microcap Event
Full Press ReleaseSEC FilingsOur ACON Tweets

About Gravity Analytica

Recent News

  • 11.15.2024 - Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Recent Filings

  • 01.22.2025 - PRE 14A Other preliminary proxy statements
  • 01.21.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 01.17.2025 - 8-K Current report

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

BROOMFIELD, CO / November 14, 2024 /Aclarion, Inc.,("Aclarion" or the "Company") (Nasdaq:ACON)(Nasdaq:ACONW),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its participation at the upcoming Virtual Investor Summit Microcap Event on November 21st. The Company will be available for 1-on-1 meetings throughout the day in addition to its formal presentation.

Event:Q4 Investor Summit
Presentation date and time:November 21, 2024, 3:30pm - 4:00pm ET
Location:https://www.webcaster4.com/Webcast/Page/3075/51667

  • The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.

  • Take a deep dive with the best Investors in MicroCap

  • Live Q & A

  • Complimentary to Qualified Investors. Please REGISTERHERE.

About the Investor Summit

The Investor Summitis an exclusive, independent conference dedicated to connecting small cap and microcap companies with qualified investors. Founded in 2015.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visitwww.aclarion.com.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media Contacts:

Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com

SOURCE:Aclarion, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com